The long-term goal of this project is to develop novel targeted therapy for human pancreatic cancer (pancreatic ductal adenocarcinoma, PDA). PDA is a devastating disease with low survival rate and short survival time. The current systemic therapy has only marginal benefit to PDA patients. There is an urgent need for the development of effective and safe therapy for PDA. The loss of tumor suppressor (e.g., p53) and/or the overexpression of oncogenes (e.g., MDM2 and ?-catenin) have been linked to resistant to treatment and poor prognosis in PDA patients. The oncogene MDM2 is a negative regulator of p53 and has been suggested to be a valid molecular target for cancer therapy. Up to date, the majority of small molecule inhibitors (SMIs) of MDM2 have been designed to block the MDM2-p53 binding, reactivating the p53 function. However, the majority of PDA harbors mutant p53 and has high levels of MDM2;these MDM2 SMIs are expected to have low or no efficacy against PDA. Therefore, it is highly desirable to design novel MDM2 SMIs that have direct effects on MDM2 and exert their anticancer activity, independent of p53 status. Based on this new conceptual framework, the applicants have designed a series of novel, highly selective MDM2 SMIs, i.e. 1-aryl and 1- heteroaryl pyrido[b]indole derivatives and generated preliminary data to provide a basis for further development of the lead compounds as novel therapeutics for PDA treatment. These SMIs directly bind to MDM2, induce MDM2 degradation, inhibit cell growth, and induce apoptosis in PDA cells. One of the lead compounds, SP141, has significant in vitro activity, in vivo efficacy, and minimal host toxicity. When investigating its mechanisms o action, the applicants discovered a secondary target of SP141: inhibiting ?-catenin expression and its transactivation activity in PDA cells. In this proposal, the applicants will test the centrl hypothesis that SP141 is a novel effective and safe therapeutic agent for the treatment of human PDA and exerts its anti-PDA activity through targeting both MDM2 and ?-catenin. Four hypothesis-driven specific aims are proposed: 1) to demonstrate the in vivo efficacy of SP141 in various PDA models, including orthotopic, transgenic, and primary tumor-derived models;2) to demonstrate that targeting MDM2 is the major mechanism of action for SP141-mediated anti-PDA activity;3) to elucidate the role of ?-catenin inhibition in SP141- mediated anticancer activity;and 4) to characterize the pharmacological and toxicological properties of SP141 in PDA-relevant models. Upon completion of these proposed studies, the anticipated results will provide information on the therapeutic efficacy and safety of SP141 and the validation of the novel drug design strategy of targeting both MDM2 and ?-catenin in PDA. It is expected that this project will generate in a novel clinical candidate for PDA therapy, which would have a major impact on patient care and public health and that the mechanistic studies will shed more lights on the role of MDM2 and ?-catenin in PDA development, progression, and therapy.
Pancreatic cancer has low survival rate and short survival time;there is an urgent need for the development of effective and safe therapy for this disease. The applicants have recently discovered a novel class of anticancer agents that exert anti-pancreatic cancer activity through targeting two cancer-causing genes, MDM2 and ?-catenin. This project will test the lead compound (called SP141) for its therapeutic efficacy and safety in clinically relevant pancreatic cancer models and the expected results would have a major impact on patient care and public health by preparing this compound for entering clinical trials.
|Yu, Junxian; Li, Zhe; Wang, Wei et al. (2016) Anticancer 20(R)-dammarane-3Î²,12Î²,20,25-tetrol-loaded polymeric micelles: Preparation, quantification and pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci 1022:13-20|
|Qin, Jiang-Jiang; Sarkar, Sushanta; Voruganti, Sukesh et al. (2016) Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy. J Biomed Res 30:322-33|
|Qin, Jiang-Jiang; Wang, Wei; Sarkar, Sushanta et al. (2016) Oral delivery of anti-MDM2 inhibitor SP141-loaded FcRn-targeted nanoparticles to treat breast cancer and metastasis. J Control Release 237:101-14|
|Wang, Wei; Nag, Subhasree; Zhang, Ruiwen (2016) Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models. Methods Mol Biol 1406:271-87|
|Qin, Jiang-Jiang; Wang, Wei; Sarkar, Sushanta et al. (2016) Inulanolide A as a new dual inhibitor of NFAT1-MDM2 pathway for breast cancer therapy. Oncotarget 7:32566-78|
|Qin, Jiang-Jiang; Wang, Wei; Voruganti, Sukesh et al. (2015) Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation. Oncotarget 6:2623-40|
|Nag, Subhasree; Qin, Jiang-Jiang; Voruganti, Sukesh et al. (2015) Development and validation of a rapid HPLC method for quantitation of SP-141, a novel pyrido[b]indole anticancer agent, and an initial pharmacokinetic study in mice. Biomed Chromatogr 29:654-63|
|Wang, Wei; Nag, Subhasree A; Zhang, Ruiwen (2015) Targeting the NFÎºB signaling pathways for breast cancer prevention and therapy. Curr Med Chem 22:264-89|
|Voruganti, Sukesh; Qin, Jiang-Jiang; Sarkar, Sushanta et al. (2015) Oral nano-delivery of anticancer ginsenoside 25-OCH3-PPD, a natural inhibitor of the MDM2 oncogene: Nanoparticle preparation, characterization, in vitro and in vivo anti-prostate cancer activity, and mechanisms of action. Oncotarget 6:21379-94|
|Qin, Jiang-Jiang; Wang, Wei; Voruganti, Sukesh et al. (2015) Inhibiting NFAT1 for breast cancer therapy: New insights into the mechanism of action of MDM2 inhibitor JapA. Oncotarget 6:33106-19|
Showing the most recent 10 out of 19 publications